P2X3 P2X2/3 Receptor Modulating Compounds for Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain associated with P2X3 and P2X2/3 receptor activation are not potent or selective enough, leading to inadequate management of conditions such as inflammatory thermal hyperalgesia, spontaneous pain, and visceral pain.
Innovation Solution
Development of novel compounds with specific structures that modulate the P2X3 and P2X2/3 pathways, including compounds of formula (I), (II), (III), and (IV), which can be administered alone or in combination with pharmaceutically acceptable salts or prodrugs, to inhibit or regulate receptor activity, thereby treating pain effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pain associated with P2X3 and P2X2/3 receptor activation are used, then pain management is provided, but the treatment is not potent or selective enough
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I, II, III, IV) that target particular receptor sites on P2X3 and P2X2/3 receptors. The compounds contain specific functional groups and structural features that interact with distinct regions of the receptor binding pocket, enabling selective modulation of these particular purinergic receptors while sparing other receptor types.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent groups (R1-R6), molecular weight, lipophilicity, and stereochemistry to optimize both potency and selectivity. By adjusting these chemical parameters, the compounds achieve enhanced binding affinity for P2X3/P2X2/3 receptors while maintaining selectivity against other purinergic and non-purinergic receptors.
2Reliability
If novel compounds with specific structures are developed to modulate P2X3 and P2X2/3 pathways, then receptor activity is inhibited effectively, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex receptor binding interface into distinct molecular components. The compounds consist of modular structural elements (core heterocyclic rings, linking chains, terminal functional groups) that can be independently optimized. This segmentation allows systematic structure-activity relationship studies where individual components are varied to enhance potency without proportionally increasing overall complexity.
Solution Approach 2:
The patent uses parameter changes to balance complexity and efficacy by optimizing key molecular parameters such as molecular weight (typically 300-600 Da), logP values, and the number of hydrogen bond donors/acceptors. These parameter optimizations ensure that while compounds have sufficient structural complexity for selective binding, they remain within pharmacologically acceptable ranges for drug-like properties and metabolic stability.
Data Source
AI summary
The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.